What is the appropriate initial work‑up and treatment plan for a patient newly diagnosed with vulvar cancer?

Initial Work-Up and Treatment for Newly Diagnosed Vulvar Cancer

For a patient newly diagnosed with vulvar cancer, proceed immediately with comprehensive staging evaluation including chest imaging, consider pelvic MRI for tumors >2 cm, and plan surgical resection with 1-2 cm margins plus inguinofemoral lymph node assessment (sentinel lymph node biopsy or lymphadenectomy) based on tumor characteristics 1.

Initial Diagnostic Work-Up

Clinical Assessment

Perform thorough examination documenting:

• Exact tumor size, location relative to vulvar midline (within or beyond 2 cm), and depth of invasion
• Proximity to critical structures (urethra, anus, vagina)
• Clinical assessment of inguinofemoral lymph nodes bilaterally
• Cervical/vaginal cytology screening for concurrent lower genital tract neoplasia 1

Imaging Strategy

For all patients:

• Chest imaging with plain radiography; if abnormal, proceed to chest CT without contrast 1

For T2 or larger tumors or suspected metastasis:

• Consider whole body PET/CT or chest/abdominal/pelvic CT 1
• Consider pelvic MRI to aid surgical and/or radiation treatment planning 1, 2

Rationale: MRI provides superior soft-tissue contrast for defining local tumor extent, particularly for tumors >2 cm with >1 mm stromal invasion or those near critical structures 2. However, normal imaging does not exclude lymph node metastases and does not eliminate the need for surgical lymph node assessment.

Laboratory Assessment

• CBC, BUN, creatinine as clinically indicated 1

Surgical Staging and Treatment Algorithm

Stage IA Disease (Tumor <1 mm invasion)

• Wide local excision with 1-2 cm margins
• No lymphadenectomy required (lymphatic metastasis risk <1%) 1
• Observation only

Stage IB-II Disease (Tumor >1 mm invasion)

Lymph node assessment is mandatory (>8% risk of lymphatic metastases) 1

For Lateral Tumors (≥2 cm from vulvar midline, <4 cm size, clinically negative nodes):

• Radical local excision or modified radical vulvectomy with 1-2 cm margins
• Unilateral inguinofemoral lymphadenectomy OR sentinel lymph node biopsy (SLNB) 1

For Midline Tumors (within 2 cm of midline or crossing midline):

• Radical local excision or modified radical vulvectomy with 1-2 cm margins
• Bilateral inguinofemoral lymphadenectomy OR bilateral SLNB 1

Sentinel Lymph Node Biopsy Criteria

SLNB is appropriate ONLY when ALL criteria are met 1:

• Unifocal tumor <4 cm
• Clinically negative inguinofemoral lymph nodes on examination and imaging
• Tumor located ≥2 cm from vulvar midline (for unilateral SLNB)
• No previous vulvar surgery disrupting lymphatic flow
• High-volume surgeon with adequate experience

Critical technical points 1:

• Use both technetium-99m sulfur colloid (injected 2-4 hours pre-operatively) AND Isosulfan Blue 1% dye (3-4 cc injected peri-tumorally at 2,5,7,10 o'clock positions 15-30 minutes before procedure)
• Perform SLNB before excising primary tumor to avoid disrupting lymphatic drainage
• If ipsilateral SLN not detected, proceed immediately to complete inguinofemoral lymphadenectomy 1

Locally Advanced Disease (Stage III-IV)

For resectable disease with bulky nodes or T3 tumors:

• Consider neoadjuvant chemoradiation with platinum-based chemotherapy 1
• If complete response not achieved, surgical resection of residual disease
• Include bilateral inguinofemoral lymphadenectomy 3

For unresectable disease requiring exenteration:

• Primary definitive chemoradiation with concurrent platinum-based chemotherapy 1
• Weekly cisplatin is current standard of care 3
• Biopsy tumor bed post-treatment to confirm pathologic complete response 3

Management Based on Surgical Pathology

Negative Lymph Nodes

• Observation if margins adequate (≥8 mm) 1

Positive Sentinel Lymph Node

If micrometastasis (<2 mm):

• Adjuvant radiation to affected groin(s) 3

If macrometastasis (≥2 mm):

• Complete inguinofemoral lymphadenectomy OR radiation to affected groin(s)
• Consider concurrent chemotherapy with radiation 3
• Evaluate/treat contralateral groin surgically or with radiation 1

Multiple Positive Nodes (>2 nodes or N2/N3 disease)

• Bilateral groin and pelvic radiation with concurrent platinum-based chemotherapy 3
• This approach significantly improves survival (68% vs 54% 2-year survival compared to surgery alone, p=0.03) 3

Close or Positive Margins (<8 mm)

Decision algorithm 1:

• If margins involve urethra, anus, or vagina: Adjuvant radiation (re-resection causes unacceptable morbidity and quality of life impact)
• If margins are elsewhere and patient has negative nodes: Consider re-resection vs. adjuvant radiation
• If patient has positive nodes requiring chemoradiation: Do not re-resect—proceed directly to chemoradiation as planned

Critical Pitfalls to Avoid

1. Do not perform SLNB if imaging shows suspicious lymph nodes—proceed directly to complete lymphadenectomy or US-guided FNAB 2

2. Do not use inadequate radiation depth—historical 3 cm depth is insufficient; use CT-based treatment planning to ensure adequate nodal coverage 3

3. Do not delay adjuvant treatment—initiate within 6-8 weeks post-operatively once adequate healing achieved 1

4. Do not perform en bloc resection—current standard uses separate incisions for tumor and lymph nodes to reduce morbidity 1

5. Lymph node status is the most important determinant of survival—never omit appropriate nodal assessment 1

Radiation Therapy Specifications (When Indicated)

Adjuvant setting 1:

• 50.4 Gy in 1.8 Gy fractions to groins/pelvis
• CT-based treatment planning mandatory
• 3D conformal or IMRT acceptable if adequate coverage ensured

Definitive/unresectable disease 1:

• 59.4-64.8 Gy in 1.8 Gy fractions
• Bulky nodes may receive boost to ~70 Gy
• Concurrent platinum-based chemotherapy